Abstract
The cornea in most species is physiologically avascular, and thus this assay allows the measurement of newly formed vessels. The continuous monitoring of neovascular growth in the same animal allows the evaluation of drugs acting as suppressors or stimulators of angiogenesis. Under anesthesia a micropocket is produced in the cornea thickness and the angiogenesis stimulus (tumor tissue, cell suspension, growth factor) is placed into the pocket in order to induce vascular outgrowth from the limbal capillaries. Neovascular development and progression can be modified by the presence of locally released or applied inhibitory factors or by systemic treatments. In this chapter the experimental details of the avascular cornea assay, the technical challenges, and advantages and disadvantages in different species are discussed. Protocols for local drug treatment and tissue sampling for histology and pharmacokinetic profile are reported.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Jain RK, Schlenger K, Hockel M, Yuan F (1997) Quantitative angiogenesis assays: progress and problems. Nat Med 3:1203–1208
Chang JH, Gabison EE, Kato T, Azar DT (2001) Corneal neovascularization. Curr Opin Ophthalmol 12:242–249
Ellenberg D, Azar DT, Hallak JA, Tobaigy F, Han KY, Jain S et al (2010) Novel aspects of corneal angiogenic and lymphangiogenic privilege. Prog Retin Eye Res 29:208–248
Maddula S, Davis DK, Maddula S, Burrow MK, Ambati BK (2011) Horizons in therapy for corneal angiogenesis. Ophthalmology 118:591–599
Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T et al (2006) Corneal avascularity is due to soluble VEGF receptor-1. Nature 443:993–997
Gimbrone M Jr, Cotran R, Leapman SB, Folkman J (1974) Tumor growth and neovascularization: an experimental model using the rabbit cornea. J Natl Cancer Inst 52:413–427
Langer R, Folkman J (1976) Polymers for the sustained release of proteins and other macromolecules. Nature 363:797–800
Brem SS, Gullino PM, Medina D (1977) Angiogenesis: a marker for neoplastic transformation of mammary papillary hyperplasia. Science 195(4281):880–882
Cervenak L, Morbidelli L, Donati D, Donnini S, Kambayashi T, Wilson J et al (2000) Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by Interleukin-10. Blood 96:2568–2573
Woolard J, Wang WY, Bevan HS, Qiu Y, Morbidelli L, Pritchard-Jones RO et al (2004) VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res 64:7822–7835
Marconcini L, Marchio S, Morbidelli L, Cartocci E, Albini A, Ziche M et al (1999) c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc Natl Acad Sci U S A 96:9671–9676
Brem H, Folkman J (1975) Inhibition of tumor angiogenesis mediated by cartilage. J Exp Med 141:427–439
Bard RH, Mydlo JH, Freed SZ (1986) Detection of tumor angiogenesis factor in adenocarcinoma of kidney. Urology 27:447–450
Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA et al (1998) Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 90:587–596
da Silva BB, da Silva RG Jr, Borges US, da Silveira Filho MA, Pimentel IC et al (2005) Quantification of angiogenesis induced in rabbit cornea by breast carcinoma of women treated with tamoxifen. J Surg Oncol 90:77–80
Ziche M, Morbidelli L, Choudhuri R, Zhang H-T, Donnini S, Granger HJ et al (1997) Nitric oxide-synthase lies downstream of vascular endothelial growth factor but not basic fibroblast growth factor induced angiogenesis. J Clin Invest 99:2625–2634
Lasagna N, Fantappiè O, Solazzo M, Morbidelli L, Marchetti S, Cipriani G et al (2006) Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. Cancer Res 66:2673–2682
Ziche M, Morbidelli L (2009) Molecular regulation of tumour angiogenesis by nitric oxide. Eur Cytokine Netw 20:164–170
Ziche M, Morbidelli L, Masini E, Amerini S, Granger HJ, Maggi CA et al (1994) Nitric oxide mediates angiogenesis in vivo and endothelial cell growth and migration in vitro promoted by substance P. J Clin Invest 94:2036–2044
Monti M, Donnini S, Morbidelli L, Giachetti A, Mochly-Rosen D, Mignatti P et al (2013) PKCε activation promotes FGF-2 exocytosis and induces endothelial cell proliferation and sprouting. J Mol Cell Cardiol 63:107–117
Muthukkaruppan V, Auerbach R (1979) Angiogenesis in the mouse cornea. Science 206:1416–1418
Chen C, Parangi S, Tolentino MT, Folkman J (1995) A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 55:4230–4233
Voest EE, Kenyon BM, O’Really MS, Truitt G, D’Amato RJ, Folkman J (1995) Inhibition of angiogenesis in vivo by interleukin 12. J Natl Cancer Inst 87:581–586
Polverini PJ, Leibovich SJ (1984) Induction of neovascularization in vivo and endothelial cell proliferation in vitro by tumor associated macrophages. Lab Invest 51:635–642
Ziche M, Jones J, Gullino PM (1982) Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 69:475–482
Taraboletti G, Morbidelli L, Donnini S, Parenti A, Granger HJ, Giavazzi R et al (2000) The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinases and TIMP-2 in endothelial cells. FASEB J 14:1674–1676
Parenti A, Morbidelli L, Ledda F, Granger HJ, Ziche M (2001) The bradykinin/B1 receptor promotes angiogenesis by upregulation of endogenous FGF-2 in endothelium via the nitric oxide synthase pathway. FASEB J 15:1487–1489
Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M (2003) Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 9:5358–5369
Bagli E, Stefaniotou M, Morbidelli L, Ziche M, Psillas K, Murphy C et al (2004) Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3′-kinase activity. Cancer Res 64:7936–7946
Donnini S, Finetti F, Lusini L, Morbidelli L, Cheynier V, Barron D et al (2006) Divergent effects of quercetin conjugates on angiogenesis. Br J Nutr 95:1016–1023
Ziche M, Alessandri G, Gullino PM (1989) Gangliosides promote the angiogenic response. Lab Invest 61:629–634
Cantara S, Donnini S, Morbidelli L, Giachetti A, Schulz R, Memo M et al (2004) Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. FASEB J 18:1943–1945
Federman JL, Brown GC, Felberg NT, Felton SM (1980) Experimental ocular angiogenesis. Am J Ophthalmol 89:231–237
Presta M, Rusnati M, Belleri M, Morbidelli L, Ziche M, Ribatti D (1999) Purine analog 6-methylmercaptopurine ribose inhibits early and late phases of the angiogenesis process. Cancer Res 59:2417–2424
Acknowledgements
The work was supported by the Italian Ministry of University (MIUR), the Italian Association for Cancer Research (AIRC) to M.Z. and Istituto Toscano Tumori (ITT) to L.M.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Ziche, M., Morbidelli, L. (2015). The Corneal Pocket Assay. In: Ribatti, D. (eds) Vascular Morphogenesis. Methods in Molecular Biology, vol 1214. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1462-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1462-3_2
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1461-6
Online ISBN: 978-1-4939-1462-3
eBook Packages: Springer Protocols